Evaluation of Serum sCD30 in Renal Transplantation Patients With and Without Acute Rejection

C. Cervelli, G. Fontecchio, M. Scimitarra, R. Azzarone, A. Famulari, F. Pisani, C. Battistoni, B. Di Iulio, D. Fracassi, M. A. Scarnecchia, F. Papola

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Despite new immunosuppressive approaches, acute rejection episodes (ARE) are still a major cause of early kidney dysfunction with a negative impact on long-term allograft survival. Noninvasive markers able to identify renal ARE earlier than creatinine measurement include sCD30. We sought to establish whether circulating levels of sCD30 in pretransplantation and posttransplantation periods were of clinical relevance to avoid graft damage. Quantitative detection of serum sCD30 was performed using an enzyme-linked immunosorbent assay. Our results demonstrated that the mean concentrations of sCD30 were significantly higher in the sera of renal transplant recipients with ARE (30.04 U/mL) and in uremic patients on the waiting list (37.7 U/mL) compared with healthy controls (HC; 9.44 U/mL), but not nonrejecting patients (12.01 U/mL). Statistical analysis revealed a strong association between high sCD30 levels in posttransplantation sera and ARE risk. This study suggested that sCD30 levels were a reliable predictor of ARE among deceased-donor kidney recipients.

Original languageEnglish
Pages (from-to)1159-1161
Number of pages3
JournalTransplantation Proceedings
Volume41
Issue number4
DOIs
Publication statusPublished - May 2009

Fingerprint

Kidney Transplantation
Kidney
Serum
Waiting Lists
Immunosuppressive Agents
Allografts
Creatinine
Enzyme-Linked Immunosorbent Assay
Tissue Donors
Transplants

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Evaluation of Serum sCD30 in Renal Transplantation Patients With and Without Acute Rejection. / Cervelli, C.; Fontecchio, G.; Scimitarra, M.; Azzarone, R.; Famulari, A.; Pisani, F.; Battistoni, C.; Di Iulio, B.; Fracassi, D.; Scarnecchia, M. A.; Papola, F.

In: Transplantation Proceedings, Vol. 41, No. 4, 05.2009, p. 1159-1161.

Research output: Contribution to journalArticle

Cervelli, C, Fontecchio, G, Scimitarra, M, Azzarone, R, Famulari, A, Pisani, F, Battistoni, C, Di Iulio, B, Fracassi, D, Scarnecchia, MA & Papola, F 2009, 'Evaluation of Serum sCD30 in Renal Transplantation Patients With and Without Acute Rejection', Transplantation Proceedings, vol. 41, no. 4, pp. 1159-1161. https://doi.org/10.1016/j.transproceed.2009.03.077
Cervelli, C. ; Fontecchio, G. ; Scimitarra, M. ; Azzarone, R. ; Famulari, A. ; Pisani, F. ; Battistoni, C. ; Di Iulio, B. ; Fracassi, D. ; Scarnecchia, M. A. ; Papola, F. / Evaluation of Serum sCD30 in Renal Transplantation Patients With and Without Acute Rejection. In: Transplantation Proceedings. 2009 ; Vol. 41, No. 4. pp. 1159-1161.
@article{d4a1f59c2bec405fb711ca39b3d65606,
title = "Evaluation of Serum sCD30 in Renal Transplantation Patients With and Without Acute Rejection",
abstract = "Despite new immunosuppressive approaches, acute rejection episodes (ARE) are still a major cause of early kidney dysfunction with a negative impact on long-term allograft survival. Noninvasive markers able to identify renal ARE earlier than creatinine measurement include sCD30. We sought to establish whether circulating levels of sCD30 in pretransplantation and posttransplantation periods were of clinical relevance to avoid graft damage. Quantitative detection of serum sCD30 was performed using an enzyme-linked immunosorbent assay. Our results demonstrated that the mean concentrations of sCD30 were significantly higher in the sera of renal transplant recipients with ARE (30.04 U/mL) and in uremic patients on the waiting list (37.7 U/mL) compared with healthy controls (HC; 9.44 U/mL), but not nonrejecting patients (12.01 U/mL). Statistical analysis revealed a strong association between high sCD30 levels in posttransplantation sera and ARE risk. This study suggested that sCD30 levels were a reliable predictor of ARE among deceased-donor kidney recipients.",
author = "C. Cervelli and G. Fontecchio and M. Scimitarra and R. Azzarone and A. Famulari and F. Pisani and C. Battistoni and {Di Iulio}, B. and D. Fracassi and Scarnecchia, {M. A.} and F. Papola",
year = "2009",
month = "5",
doi = "10.1016/j.transproceed.2009.03.077",
language = "English",
volume = "41",
pages = "1159--1161",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Evaluation of Serum sCD30 in Renal Transplantation Patients With and Without Acute Rejection

AU - Cervelli, C.

AU - Fontecchio, G.

AU - Scimitarra, M.

AU - Azzarone, R.

AU - Famulari, A.

AU - Pisani, F.

AU - Battistoni, C.

AU - Di Iulio, B.

AU - Fracassi, D.

AU - Scarnecchia, M. A.

AU - Papola, F.

PY - 2009/5

Y1 - 2009/5

N2 - Despite new immunosuppressive approaches, acute rejection episodes (ARE) are still a major cause of early kidney dysfunction with a negative impact on long-term allograft survival. Noninvasive markers able to identify renal ARE earlier than creatinine measurement include sCD30. We sought to establish whether circulating levels of sCD30 in pretransplantation and posttransplantation periods were of clinical relevance to avoid graft damage. Quantitative detection of serum sCD30 was performed using an enzyme-linked immunosorbent assay. Our results demonstrated that the mean concentrations of sCD30 were significantly higher in the sera of renal transplant recipients with ARE (30.04 U/mL) and in uremic patients on the waiting list (37.7 U/mL) compared with healthy controls (HC; 9.44 U/mL), but not nonrejecting patients (12.01 U/mL). Statistical analysis revealed a strong association between high sCD30 levels in posttransplantation sera and ARE risk. This study suggested that sCD30 levels were a reliable predictor of ARE among deceased-donor kidney recipients.

AB - Despite new immunosuppressive approaches, acute rejection episodes (ARE) are still a major cause of early kidney dysfunction with a negative impact on long-term allograft survival. Noninvasive markers able to identify renal ARE earlier than creatinine measurement include sCD30. We sought to establish whether circulating levels of sCD30 in pretransplantation and posttransplantation periods were of clinical relevance to avoid graft damage. Quantitative detection of serum sCD30 was performed using an enzyme-linked immunosorbent assay. Our results demonstrated that the mean concentrations of sCD30 were significantly higher in the sera of renal transplant recipients with ARE (30.04 U/mL) and in uremic patients on the waiting list (37.7 U/mL) compared with healthy controls (HC; 9.44 U/mL), but not nonrejecting patients (12.01 U/mL). Statistical analysis revealed a strong association between high sCD30 levels in posttransplantation sera and ARE risk. This study suggested that sCD30 levels were a reliable predictor of ARE among deceased-donor kidney recipients.

UR - http://www.scopus.com/inward/record.url?scp=65549140598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549140598&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2009.03.077

DO - 10.1016/j.transproceed.2009.03.077

M3 - Article

VL - 41

SP - 1159

EP - 1161

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 4

ER -